Randomized

NKGen Biotech Advances Alzheimer’s Treatment with SNK01: First Patient Dosed in Phase 1/2a Trial

Source Node:
Time Stamp: December 29, 2023 3:07 AM - Modified On: December 29, 2023 - Published By:
Source Cluster:
Republished By Plato

December 29, 2023 - NKGen Biotech, Inc. (Nasdaq: NKGN) is making strides in Alzheimer's disease (AD) treatment with the dosing of the first patient in its Phase 1/2a trial for SNK01, an autologous natural killer (NK) cell therapy. The innovative product, designed for moderate AD, has demonstrated promising results in neuroinflammation and cognitive function during its Phase 1 safety trial. Key Points: SNK01 Efficacy: NKGen's SNK01, a cryopreserved autologous NK cell therapy, showed improvement in neuroinflammation and cognitive function in the Phase 1 dose-escalation safety trial. The therapy boasts enhanced

Cardiol Therapeutics (NASDAQ: CRDL) Advancements in Therapies for Inflammatory Heart Diseases

Source Node:
Time Stamp: October 13, 2023 5:16 AM - Modified On: October 13, 2023 - Published By:
Source Cluster:
Republished By Plato

In the United States, heart disease accounts for a significant number of deaths every year, with cardiovascular disease being the primary concern. Factors like lifestyle choices and unforeseen circumstances contribute to its prevalence. Myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the heart's lining) are two inflammatory heart conditions primarily linked to immunological reactions from viral infections and mRNA vaccines. Though considered rare, awareness of these conditions is growing, especially among younger populations. Recent research in Science Immunology highlighted an increase in cytokine production leading to myocarditis in

Coya Therapeutics Reports Additional Biomarker and Imaging Data Showing Decrease in Neuroinflammation with COYA 301 in Alzheimer’s Disease.

Source Node:
Time Stamp: June 7, 2023 12:21 PM - Modified On: June 7, 2023 - Published By:
Source Cluster:
Republished By Plato

Highlights Coya reports new data illustrating that administration of COYA 301 (low dose Interleukin-2 (IL-2)) in an open- label study in 8 patients with mild to moderate AD (COYA 301 Trial) resulted in a statistically significant reduction in the expression of three well characterized proinflammatory cytokines -- Tumor Necrosis Factor alpha (TNF-α), Interleukin 6 (IL-6), and Interleukin 1- Beta (IL-1β) -- which correlated with lack of cognitive decline of the patients over the course of the study. TNF-α is one of the main inflammatory cytokines involved in initiating and propagating

Kryptomon to list KMON token on Gate.io in partnership with its first Tier-1 CEX

Source Node: https://ambcrypto.com/kryptomon-to-list-kmon-token-on-gate-io-in-partnership-with-its-first-tier-1-cex/
Time Stamp: November 17, 2021 6:30 AM - Modified On: November 17, 2021 - Published By:
Source Cluster:
Republished By Plato

Kryptomon is pleased to announce its token $KMON on Gate.io, following the sale of its first Legendary Kryptomon for an eye-watering $49,700 in the first-ever Kryptomon auction, the Kryptomon team seem to have no intention of resting on their laurels.  In an overwhelming outpouring of support from Binance users worldwide, not only did all 2000 Kryptomon Mystery Boxes sell out on the BinanceNFT marketplace in a reported 0.27 seconds, those same mystery boxes have generated a trading volume of almost $1M on the secondary resell market just days after listing. 

Memenopoly Announces Strategic Partnership with Babylons NFT

Source Node: https://www.livebitcoinnews.com/memenopoly-announces-strategic-partnership-with-babylons-nft/
Time Stamp: August 22, 2021 6:47 AM - Modified On: August 22, 2021 - Published By:
Source Cluster:
Republished By Plato

Atlanta, United States / August 21, 2021 / Memenopoly, a new coming of age gaming NFT solution, has announced a strategic partnership with the first community-owned NFT marketplace Babylon. The partnership would allow Meme-themed Memenopoly NFTs to be auctioned on Babylons NFT marketplace. Memenopoly is a yield generating blockchain “play to earn” game. The platform aims to bring the next evolution of gamified yield generation, leveraging the power of NFTs to reward players and farmers. Memenpoly has made the game of Monopoly more interesting, offering earning opportunities with an NFT

Race cars and earn cryptocurrency with Riot Racers

Source Node: https://ambcrypto.com/race-cars-and-earn-cryptocurrency-with-riot-racers/
Time Stamp: July 28, 2021 10:00 AM - Modified On: July 28, 2021 - Published By:
Source Cluster:
Republished By Plato

The gaming industry has grown exponentially in the past few years, and the play-to-earn gaming model is leading the way with an innovative approach that puts the gamer in the driver’s seat. Play-to-earn is a relatively newer concept that allows players to own part of the game, earn cryptocurrency-backed tokens by playing, and later trade or exchange earned tokens for fiat on cryptocurrency exchanges. While the play-to-earn gaming industry has seen steady growth recently, many of the games have become too expensive to start playing, with the cost to play

Ampleforth Down 66% — Welcome to Rebasing

Source Node: https://beincrypto.com/ampleforth-down-66-welcome-to-rebasing/
Time Stamp: August 9, 2020 9:55 AM - Modified On: May 21, 2021 - Published By:
Source Cluster:
Republished By Plato

The elastic supply token Ampleforth (AMPL) has lost two-thirds of its market cap in a matter of days. The atypical characteristics of the token attracted many investors that jumped in. After a dramatic surge in price and market cap, the tables have turned and Ampleforth has entered a corrective phase. The token is understood by many as just an experiment, and it may impact the way future tokens are created. AMPL: The Ultimate Digital Money? Ampleforth is not your typical cryptocurrency. It’s quite a complex token with some revolutionary ideas,